Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | IL2 | P60568 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18130718 | 0.86 | LMNA (0.45) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL471858 | 0.86 | KDM4E (0.60) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL2678996 | 0.85 | KDM4E (0.46) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL7513299 | 0.85 | KDM4E (0.44) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL707643 | 0.85 | KDM4E (0.49) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL3751992 | 0.81 | LMNA (0.55) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL5378874 | 0.80 | KIF11 (0.42) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL3030444 | 0.80 | HRH3 (0.50) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL5227880 | 0.79 | KDM4E (0.53) | LMNAMAPTHTTKDM4EHRH3 | |
| SCHEMBL20409590 | 0.79 | KDM4E (0.53) | LMNAMAPTHTTKDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101925575-B | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanillic acid receptor antagonist | AMOREPACIFIC CORP | 2014-06-18 | — | — | CN | disclosed |
| EP-2238105-B1 | NOVEL COMPOUNDS AS VANILLOID RECEPTOR ANTAGONISTS | AMOREPACIFIC CORP (KR) | 2014-04-16 | — | — | EP | disclosed |
| EP-2238105-B1 | NOVEL COMPOUNDS AS VANILLOID RECEPTOR ANTAGONISTS | AMOREPACIFIC CORP (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2014-01-09 | — | — | US | disclosed |
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2014-01-09 | — | — | US | disclosed |
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2014-01-09 | — | — | US | disclosed |
| US-8557872-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2013-10-15 | — | — | US | disclosed |
| US-8557872-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2013-10-15 | — | — | US | disclosed |
| US-8557872-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2013-10-15 | — | — | US | disclosed |
| US-20110015230-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-01-20 | — | — | US | disclosed |
| EP-0984963-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-04-11 | — | — | EP | disclosed |
| US-6162808-A | Compounds | ASTRAZENECA U.K. LIMITED (GB) | 2000-12-19 | — | — | US | disclosed |
| US-6133286-A | ANTAGONISTS; ANTIINFLAMMATORY AGENTS FOR RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHER SKIN DISORDERS, E.G., ECZEMA, ERYTHEMA, PRURITUS AND ACNE; STROKE, REPERFUSION INJURY, GRAFTING | PFIZER INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6051601-A | USEFUL OF INFLAMMATORY DISORDERS INCLUDING RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHER SKIN DISORDERS SUCH AS ECZEMA, ERYTHEMA, PRURITUS AND ACNE, STROKE AND OTHER FORMS OF REPERFUSLON | PFIZER INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0984963-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054180-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-12-03 | — | — | WO | disclosed |
| EP-0785930-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B 4? (LTB 4?) ANTAGONISTS | PFIZER INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011920-A1 | BENZOPYRAN AND BENZO-FUSED COMPOUNDS, THEIR PREPARATION AND THEIR USE AS LEUKOTRIENE B4 (LTB4) ANTAGONISTS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| US-5395827-A | Analgesic, anticonvulsant, antiepileptic and anxiolytic agents | GUILFORD PHARMACEUTICALS INC. (US) | 1995-03-07 | — | — | US | disclosed |
| WO-1993005772-A1 | φ-[2-(PHOSPHONOALKYL)PHENYL]-2-AMINOALKANOIC ACIDS AS ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011881-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | LMNA 4285/4885MAPT 4334/4885HTT 3226/4885 |
| US-20110015230-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | LMNA 4285/4885MAPT 4334/4885HTT 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.